Investigating how apolipoprotein M can help treat heart failure
Apolipoprotein M: a novel regulator of myocardial Autophagy
This study is looking at how a protein called ApoM might help people with heart failure feel better and live longer, especially for those who have also been treated with a cancer drug, and it hopes to find out if boosting ApoM can improve heart health without interfering with cancer treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10908403 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of apolipoprotein M (ApoM) in heart failure (HF) and its potential as a novel therapy. Researchers have found that lower levels of ApoM are linked to higher mortality rates in HF patients. By using a model that simulates heart damage caused by the cancer drug doxorubicin, the study aims to explore how increasing ApoM levels can improve heart function and survival rates. The research also examines whether ApoM affects the efficacy of doxorubicin in treating acute myeloid leukemia, ensuring that it could be a safe addition to cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with heart failure, particularly those who may also be receiving doxorubicin for cancer treatment.
Not a fit: Patients with heart failure who are not receiving doxorubicin or do not have low levels of apolipoprotein M may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for patients with heart failure.
How similar studies have performed: Other research has shown promising results in using apolipoproteins for heart-related therapies, suggesting that this approach may be viable.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Javaheri, Ali — Washington University
- Study coordinator: Javaheri, Ali
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.